Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER		PATIENT:	
Name:		. Name:	
Ward:		. NHI:	
neumo	ococcal (PPV23) polysaccharide vaccine		
Re-asses	ON – High risk patients ssment required after 3 doses sites (tick box where appropriate)		
0		ansplant, or chemotherapy; pre- or post-splenectomy; or with functional ement deficiency (acquired or inherited), cochlear implants, or primary	
Re-asses	DN – High risk children ssment required after 2 doses sites (tick boxes where appropriate)		
Terequi	Sites (lick boxes where appropriate)		
and	Patient is a child under 18 years for (re-)immunisation		
	or	vaccinate when there is expected to be a sufficient immune response	
	or With HIV infection		
	O With renal failure, or nephrotic syndrome		
		antation (including haematopoietic stem cell transplant)	
	or O With cochlear implants or intracranial shunts or		
	O With cerebrospinal fluid leaks		
		eks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg 0 kg on a total daily dosage of 20 mg or greater	
	O With chronic pulmonary disease (including asthma tre	ated with high-dose corticosteroid therapy)	
	O Pre term infants, born before 28 weeks gestation		
	O With cardiac disease, with cyanosis or failure or		
	O With diabetes		
	O With Down syndrome		
	O Who are pre-or post-splenectomy, or with functional a	splenia	
	ON – Testing for primary immunodeficiency diseases sites (tick box where appropriate)		
\circ	For use in testing for primary immunodeficiency diseases, on the	recommendation of an internal medicine physician or paediatrician	
	•		

I confirm that the above details are correct:

Signed: Date: